Shashank Kumar Singh

Shashank Kumar Singh

Auto-generated profile, based on publicly available information

Shashank Kumar Singh

Cancer Pharmacology Division, Indian Institute of Integrative Medicine, CSIR, Jammu 180001, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2022 in Heliyon
Verified
Journal Article
Open access
AQarem qayum
arem qayum
AMAsmita Magotra
Asmita Magotra
SSSyed Mohmad Shah
Syed Mohmad Shah
UNUtpal Nandi
Utpal Nandi
PSP.R. Sharma
P.R. Sharma
SSShashank Kumar Singh
Shashank Kumar Singh
β-Boswellic acid (β-BA), a potent NF-kB signaling pathway inhibitor, has shown synergistic anti-cancerous activity (NCT03149081, NCT00243022 and NCT02977936) in various clinical trials as complementary therapies. The study has been conducted to investigate the effect and efficacy of 2-pyridin-4-yl methylene β-boswellic acid (PMBA) and 5-Flourouracil (5-FU) in combination therapy for the treatment of KRAS mutant colon cancer. Analysis of isobologram showed synergistic combination index (CI > 1) of PMBA and 5-FU against the HCT-116G13D and SW-620G12V cell lines. The growth-inhibiting PMBA also caused apoptosis mediating effects with dose-dependent increase in caspase-3 activity, while inhibiting the formation of colonies in combination with 5-FU. As evident, PMBA affected colorectal 3D CSC properties including the ability to self-renew along with the expression of multi-drug resistance genes, viz., ABCB1, ABCC1 and ALDH1A1, ALDH1A2, ALDH1A3, ALDH3A1, and CSC markers like CD44, CD166, EPCAM, OCT-4, SOX-2, and NANOG compared with those in 2D model explaining the expression pattern of oncogenic KRASG13D, G12V mutation. When examined for plasma level of PMBA (20 mg) and PMBA+5-FU (20 + 40 mg), a time-dependent increase in the level of the drug (5-FU) was detected, indicating its absorption and bioavailability with excellent half-life of the PMBA for both routes of administration (IV and Oral), thereby indicating a new adjuvant therapy for KRAS mutant colon cancer.

18 April 2022 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
AQarem qayum
arem qayum
JSJasvinder Singh
Jasvinder Singh
AKArvind Kumar
Arvind Kumar
SSSyed Mohmad Shah
Syed Mohmad Shah
SSShubham Srivastava
Shubham Srivastava
SSShashank Kumar Singh
Shashank Kumar Singh